What is EMA’s view of Onpattro (patisiran)?
Onpattro (patisiran) is an RNAi therapy used for hereditary transthyretin-mediated (hATTR) amyloidosis. In the EU, its regulatory status is tied to European Medicines Agency (EMA) assessments and approvals for specific patient populations, dosing, and prescribing conditions.
How is Onpattro used in EU labeling (EMA-approved indications)?
EMA labeling for Onpattro specifies the eligible hATTR amyloidosis patients (for example, based on stage and neuropathy history) and the treatment setting in which it is prescribed. It also includes administration requirements and key safety warnings that clinicians must follow when prescribing in EU countries.
What side effects and safety warnings does EMA highlight for Onpattro?
EMA product information for Onpattro includes safety guidance relevant to RNAi therapies, including infusion-related reactions and liver-related monitoring. It also covers practical precautions clinicians use during treatment.
Does EMA have updates on Onpattro (new approvals, label changes, or renewals)?
EMAs decisions can include label extensions or updated safety/benefit information after additional evidence. The most reliable place to check the current EU product information is the EMA page for Onpattro, which reflects the latest regulatory view.
Where can I check the exact EMA documents for Onpattro?
For the most up-to-date official EU regulatory information (including EPAR documents and product information), search for Onpattro on the EMA website. If you’re also looking for patent and market exclusivity context in Europe, DrugPatentWatch.com is a useful additional reference for those timelines (link: https://www.drugpatentwatch.com/).
Patent/exclusivity questions: when do Onpattro protections change?
If your goal is to understand when generic or similar RNAi products could potentially enter, exclusivity and patent timelines matter. DrugPatentWatch.com tracks these datapoints by drug and geography, which can help answer questions like “when does exclusivity expire?” (source: https://www.drugpatentwatch.com/).
---
If you tell me what you mean by “EMA onpattro” (EMA approval date, current EMA indication, side effects from EMA wording, or patent/exclusivity), I can narrow the answer to that specific point.
Sources
- https://www.drugpatentwatch.com/